Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 738 matching trials from the live ClinicalTrials.gov search.
Conditions
Renal Insufficiency
Interventions
QAW039, QAW39A, QAW39A2107
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Kidney Diseases, End Stage Renal Disease
Interventions
telavancin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Conditions
End Stage Renal Disease (ESRD)
Interventions
ELISIO-15H, Revaclear, Optiflux
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Chronic Kidney Failure
Interventions
Kibow Biotics
Dietary Supplement
Lead sponsor
Kibow Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Thrombosis, Factor XI, Renal Impairment, ESRD (End-Stage Renal Disease)
Interventions
BMS-986177
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Uremic Pruritus
Interventions
CR845 0.5 mcg/kg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Chula Vista, California • Fountain Valley, California • Northridge, California + 25 more
Conditions
End Stage Renal Failure, Hemodialysis Access Failure, Arterio-venous Fistula
Interventions
One stage approach
Procedure
Lead sponsor
Tze-Woei Tan
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
End Stage Renal Disease, Hemodialysis
Interventions
Alpha tocopherol
Drug
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
End-Stage Renal Disease, Hepatitis C
Interventions
Zepatier, Ribavirin, Sofosbuvir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
End Stage Renal Disease
Interventions
Motivational interviewing
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
End Stage Renal Failure With Renal Transplant
Interventions
Tacrolimus with MMF, Group 2: Tacrolimus with Everolimus.
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Chronic Kidney Disease, End Stage Renal Disease, Anemia
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
4
States / cities
Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more
Conditions
Chronic Kidney Diseases, Patient Requiring Heparin Free Dialysis Treatments
Interventions
Dialyzer with Endexo
Device
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
22 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
New Bern, North Carolina
Conditions
End-Stage Kidney Disease, End-Stage Renal Disease
Interventions
Metoprolol Succinate, Carvedilol
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Long Beach, California • Aurora, Colorado • West Haven, Connecticut + 15 more
Conditions
Kidney Failure, Chronic, Catheter-Related Infections
Interventions
Neutrolin, Heparin
Drug
Lead sponsor
CorMedix Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Riverside, California • San Dimas, California • Miami Gardens, Florida + 2 more
Conditions
End-Stage Renal Disease
Interventions
Nudge for PHPC Referral
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Anemia, End Stage Renal Disease
Interventions
Individualized Anemia Mangement Protocol
Other
Lead sponsor
Michael Germain
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Chicopee, Massachusetts
Terminated Phase 2 Interventional Results available

TARGTEPO Treatment for Anemia in PD US Trial

NCT02468414
Conditions
Anemia of End Stage Renal Disease
Interventions
MDGN201 TARGTEPO
Biological
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Chronic Renal Failure, End-Stage Renal Disease
Interventions
Protein Diet
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
25 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Torrance, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Representational Intervention to Promote Preparation for End-of-life Decision Making

NCT01259011
Conditions
End Stage Renal Disease
Interventions
the SPIRIT intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Secondary Hyperparathyroidism
Interventions
Sensipar (Cinacalcet HCl)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
16
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more
Completed Phase 3 Interventional

Homocysteine Study (HOST)

NCT00032435
Conditions
End Stage Renal Disease, Renal Failure
Interventions
PAL-40 Active, PAL-40 Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Enrollment
2,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
36
States / cities
Birmingham, Alabama • Menlo Park, California • Palo Alto, California + 33 more
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTA018 Injection
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Pembroke Pines, Florida • Meridian, Idaho • Springfield, Massachusetts + 2 more
Completed Not applicable Interventional Results available

Outlook Quality of Life Intervention Study

NCT01044290
Conditions
Cancer, Congestive Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD), End Stage Renal Disease (ESRD)
Interventions
Life Completion, Attention Control
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 95 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina